Hyperpolarized 129 Xenon
Preclinical
Hyperpolarized 129 Xenon is one of 6 therapeutic programs targeting Respiratory Disorders. It is currently in Preclinical.
2
Indications
3
Total Trials
3
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
4 competitors in HSCT
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 2
Defitelio
Jazz PharmaceuticalsPhase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
N-Acetyl-L-Cysteine
PPeking University People's Hospital
Phase 2
Hyperpolarized 129 Xenon
CChildren's Hospital Medical Center, Cincinnati
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
HSCT2 trials
Technical Development of Xe MRI in Children and Adults
Enrolling by invitation·CChildren's Hospital Medical Center, Cincinnati·Preclinical·NCT07823010·550 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Hyperpolarized 129 Xenon. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]